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Newborn screening for congenital hypothyroidism: performance and




Early detection of congenital hypothyroidism (CHT), and treatment with oral
thyroxine, supports the critical period of early brain development, improves
growth and prevents the metabolic effects of adult hypothyroidism. Screening for
CHT, involving an assay for thyroid-stimulating hormone (TSH), has been
included in the UK newborn blood spot screening programme since 1981. Since
the introduction of screening, the number of CHT cases has increased, although
the reasons for this are unclear. There has been limited evaluation of the
performance of the current UK programme.
Methods
UK-wide active surveillance to estimate the current incidence of CHT in infancy
and to evaluate perfomance of the newborn screening programme. Surveillance
was conducted through the British Paediatric Surveillance Unit and newborn
screening laboratories from 2011 to 2012 to identify children aged!5 years who
were investigated after a presumptive-positive screening result or clinical
presentation. Children were followed for 3 years to confirm CHT diagnosis and
clinical management. Differences in the TSH assay cut-off used by English
laboratories provided an opportunity to explore the optimal screening test cut-off.
Results
Six hundred and twenty nine newborns (58.3% girls) were reported after
presumptive-positive screen and an additional 21 children (52.4% girls) after
clinical presentation. 508 children commenced thyroxine but this was
discontinued in 76 (15%) children. 432 (85%) remained on treatment at three
years. Incidence of CHT was 5.3 (95%CI 4.8, 5.8) per 10,000 live-births.
Screening programme sensitivity, specificity and positive predictive value were
96.76%, 99.97% and 66.88% respectively. Evaluation at different TSH cut-offs
suggested that the optimal cut-off was likely to be lower than the recommended
standard.
Discussion / Conclusion
Performance of the UK screening programme for CHT is good, however
standardisation of screen test cut-offs is advisable and re-evaluation of the
recommended cut-off is warranted. Clinical follow-up is essential to avoid
unnecessary continuation of therapy, and ascertain longer-term outcomes.
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Congenital hypothyroidism – lessons from a tertiary service
Catherine Peters
London.
Congenital hypothyroidism (CH) occurs due to dysgenesis or dyshormonogenesis
of the thyroid gland. Newborn screening for CH was introduced in the UK over 30
years ago and has almost eliminated the severe intellectual deficits caused by the
deficiency of thyroxine to the developing brain. The recognised incidence of CH
increased immediately post introduction of screening due to the improved
detection and diagnosis of cases. However, further increases in the incidence of
CH have been reported internationally and this is variably suggested to be due to a
combination of lower screening detection thresholds, changes in population
demographics and iodine status. Using data from over 1700 infants who have
been referred to a single centre with positive CH screening results, lessons have
been learnt in terms of the impact of changing screening TSH thresholds,
underlying the physiology and genetics of CH and outcome data. In this cohort,
we demonstrated that the group of infants classified as Asian/British Asian and
Chinese by the UK Office of National Statistics have higher TSH cut points than
the group of infants classified as white. This Asian group is also over-represented
in the cohort referred from the CH screening laboratory compared to the
background population. In addition, there is a high incidence of genetic mutations
in the DUOX2 pathway for infants with borderline screening results. These
mutations are reported most frequently in populations from the Asian
subcontinent. They may be associated with transient CH. Using data from this
same cohort, we have studied audiology outcomes. These suggest that there in an
increase in hearing loss in infants with CH, and this is not detected by newborn
hearing screening. In summary, 30 years after the introduction of newborn CH
screening, there are still many unanswered questions regarding the physiology,
genetics and outcomes of infants with CH.
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Subclinical hypothyroidism – lessons from clinical studies in adults
Salman Razvi
Newcastle.
Subclinical hypothyroidism (SCH) is a relatively common endocrine condition
characterised by raised serum thyrotropin (TSH) levels in the presence of normal
circulating thyroid hormones. It is generally recognised that SCH – especially if it
is sustained - is a mild form of hypothyroidism but whether it should be treated or
not is a matter of a long-standing debate amongst both paediatric as well as adult
endocrinologists. In adults, there are conflicting data on the long-term outcomes
of SCH with some studies suggesting adverse metabolic, cardiovascular,
pregnancy-related and quality of life outcomes. On the other hand, there is
emerging evidence to suggest that SCH may not be detrimental to health (or may
even be beneficial) in the very elderly. Clinical trials of treatment of SCH have
mostly shown modest benefit in reduction of cardiovascular risk factors: mainly
dyslipidaemia, but little or no improvement in other areas. Therefore, current
evidence does not support the view that all patients with SCH should be treated.
However, there may be certain groups of individuals that may gain from treatment
in adult populations. This overview will identify such groups that may be at risk of
the adverse effects of SCH and could potentially benefit from treatment.
Furthermore, how the lessons learnt from adult SCH populations could be applied
to younger groups will be discussed.
DOI: 10.1530/endoabs.51.S1.3




APS1 – an expanding disease spectrum
Catherine Owen
Newcastle.
Autoimmune Polyglandular Syndrome (APS1), also known as Autoimmune
Polyendocrinopathy-Candidiasis-Ectodermal Dystrophy (APECED), is a rare but
frequently debilitating disorder, usually presenting in childhood and adolescence;
it is typically caused by homozygous AIRE mutations. The cardinal
manifestations are chronic mucocutaneous candidiasis, autoimmune hypopar-
athyroidism and autoimmune adrenal insufficiency; the development of any two
of these three classic features leads to the diagnosis. There are many associated
minor manifestations and these may be the main presenting features. It is
becoming increasingly apparent that the involvement of non-endocrine tissues
can play a significant role in the morbidity and mortality associated with this
condition. This presentation, with the aid of cases, will consider:
† The variability of the early clinical picture and the difficulties that this poses
when making a diagnosis of APS1.
† The underlying immune deficit in APS1 and the immune markers that can
facilitate the diagnostic process.
† The diverse clinical picture that we have observed in local patients and the
management challenges associated with the non-endocrine organ-specific
manifestations.
† The need for input from multiple different paediatric specialities due to this
widening clinical picture and the role of a specialised APS1 clinic.
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